Dominates Somerville in last regular season game to go to 17-2, and clinches first ever Dual County championship.
The Cambridge Rindge and Latin baseball team (15-2) extended its winning streak to eight games last week with a 9-7 defeat of ...
On July 10, 2025, the Food and Drug Administration (FDA) announced that it had published more than 200 complete response letters (CRLs), in response to applications submitted to the FDA for approval ...
On September 4, 2025, the U.S. Food and Drug Administration (“FDA”) announced plans to begin releasing complete response letters (“CRLs”) “promptly” after it issues them to sponsors, rather than ...
In a move towards transparency, the US Food and Drug Administration (FDA) has published more than 200 archived complete response letters (CRLs), which detail reasons for non-approval of drug ...
A CRL signifies non-approval of a drug/application in its current form, but allows for issue resolution and potential approval. In 2025, the FDA began publishing CRLs to enhance transparency, ...
Increasing CRLs from the FDA highlight CMC and analytical deficiencies, often surfacing late in the review cycle, indicating a disconnect between sponsor expectations and FDA standards. Recent CRLs ...
FDA leaders claimed that publishing hundreds of complete response letters (CRLs) in a central database was embracing "radical transparency," but critics think the move was more about optics, and argue ...
In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new ...
The FDA's decision to publish complete response letters (CRLs) amounted to little more than a repackaging of existing information, but now it has gone a step further. The latest batch of CRLs to be ...
The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial review an act of "radical transparency," but it is not as revolutionary as ...